Sanchat Thanyanuch
Department of Medical Services, Central Chest Institute of Thailand, Ministry of Public Health, Nonthaburi, ThailandPublications
-
Research Article
Author(s): Sanchat Thanyanuch42984*, Chuchottaworn Charoen42985, Mahasirimongkol Surakameth42986 and Wattanapokayakit Sukanya42987
Background: The Slow Acetylator (SA) was associated with a higher risk of Anti-Tuberculosis Drug-Induced Liver Injury (AT-DILI). This study aimed to evaluate whether a lower dose of Isoniazid than that allocated in the conventional treatment, can reduce the incidence of AT-DILI in Thai SA patients. Methods: The Tuberculosis patients were screened for NAT2 gene. The SA patients were recruited in an open-label, Randomized Control Trial and randomly assigned in a 1:1 ratio to receive an adjusted or the standard Isoniazid (INH) dose in the first-line regimen. The primary outcome was the AT-DILI incidence. Results: Among 260 patients undergoing the NAT2 gene screening, the frequencies of the NAT2 acetylator were 37.30%, 49.62% and 13.08% for Slow, Intermediate and Rapid Acetylators respectivel.. Read More»